Debt (Additional Information) (Details)
|
|
|
|
|
|
|
|
|
1 Months Ended |
3 Months Ended |
6 Months Ended |
12 Months Ended |
|
|
|
|
Dec. 31, 2025
USD ($)
|
Sep. 30, 2025
USD ($)
|
Feb. 28, 2025
USD ($)
Days
|
Jan. 02, 2025
USD ($)
shares
|
Dec. 21, 2024
USD ($)
|
Oct. 08, 2024
USD ($)
$ / shares
shares
|
Sep. 23, 2024
USD ($)
|
Sep. 21, 2023
USD ($)
|
Sep. 30, 2023
USD ($)
|
Mar. 31, 2024 |
Jun. 30, 2025
USD ($)
$ / shares
shares
|
Jun. 30, 2024
USD ($)
shares
|
Dec. 31, 2026
USD ($)
|
Dec. 31, 2025
USD ($)
|
Dec. 31, 2024
USD ($)
shares
|
Jul. 22, 2025
$ / shares
shares
|
Oct. 31, 2024
shares
|
Sep. 20, 2024
USD ($)
|
Jun. 18, 2024
shares
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash proceeds for direct offering |
|
|
|
|
|
|
|
|
|
|
$ 7,000,000
|
|
|
|
|
|
|
|
|
Purchased revenue liability, current |
|
|
|
|
|
|
|
|
|
|
4,590,000
|
|
|
|
$ 4,115,000
|
|
|
|
|
Repayment of debt prinnciple installment |
|
|
|
|
|
|
|
|
|
|
0
|
$ 35,000,000
|
|
|
|
|
|
|
|
Debt, current |
|
|
|
|
|
|
|
|
|
|
$ 39,871,000
|
|
|
|
$ 34,876,000
|
|
|
|
|
Ordinary shares issued | shares |
|
|
|
|
|
|
|
|
|
|
6,955,694
|
|
|
|
6,951,622
|
|
|
|
3,250,000
|
Amortization payment |
|
|
|
$ 1,100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants exercised price | $ / shares |
|
|
|
|
|
|
|
|
|
|
$ 36.4
|
|
|
|
|
|
|
|
|
Purchased revenue liability |
|
|
|
|
|
|
|
|
|
|
$ 7,600,000
|
|
|
|
$ 6,800,000
|
|
|
|
|
Senior Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principle amount of issued debt |
|
|
|
|
|
|
|
|
$ 101,900,000
|
|
|
|
|
|
|
|
|
|
|
Net cash proceeds for direct offering |
|
|
|
|
|
|
|
|
|
|
9,578,835,000
|
|
|
|
|
|
|
|
|
Repayment of debt prinnciple installment |
|
|
|
|
$ 15,000,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Estimated fair value |
|
|
|
|
|
|
|
|
|
|
18,500,000
|
|
|
|
12,200,000
|
|
|
|
|
Debt, current |
|
|
|
|
|
|
|
|
|
|
18,500,000
|
|
|
|
12,200,000
|
|
|
|
|
Repurchase of warrants |
|
|
|
|
|
|
|
|
|
|
$ 300,000
|
|
|
|
|
|
|
|
|
Date of Maturity Start |
|
|
|
|
|
|
|
|
|
|
Sep. 23, 2024
|
|
|
|
|
|
|
|
|
Maturity Date End |
|
|
|
|
|
|
|
|
|
|
Sep. 30, 2024
|
|
|
|
|
|
|
|
|
Debt maturity date |
|
|
|
|
|
Sep. 23, 2024
|
Mar. 21, 2025
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization payment |
|
|
|
|
|
|
$ 1,700,000
|
|
|
|
|
|
|
|
|
|
|
|
|
Payment to Oramed |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,000,000
|
|
Maturity Date |
|
|
|
|
|
Sep. 23, 2024
|
Mar. 21, 2025
|
|
|
|
|
|
|
|
|
|
|
|
|
Senior Notes [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization payment |
|
|
|
|
|
|
|
|
|
|
$ 20,000,000
|
|
|
|
|
|
|
|
|
Senior Notes [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization payment |
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
Deferral and Consent under Tranche B Senior Secured Convertible Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt principal amount |
|
|
|
$ 6,250,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Redemption Premium |
|
|
|
100.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement | First installment [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Repayment of debt prinnciple installment |
|
|
|
|
|
|
|
$ 5,000,000
|
|
|
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement | Second Installment [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Repayment of debt prinnciple installment |
|
|
|
|
|
|
|
15,000,000
|
|
|
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement | Third Installment [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Repayment of debt prinnciple installment |
|
|
|
|
|
|
|
20,000,000
|
|
|
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement | Senior Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principle amount of issued debt |
|
|
|
|
|
|
|
101,900,000
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument, description |
|
|
|
|
|
|
|
|
|
Interest under the Oramed Note accrues at a fluctuating per annum interest rate equal to the sum of (1) the greater of (x) 4% and (y) Term SOFR (as defined in the Oramed Note) and (2) 8.5%, payable in-kind on a monthly basis. Pursuant to the Oramed Note, since the outstanding principal of the Oramed Note was not repaid in full on or prior to March 21, 2024, an exit fee of approximately $3.1 million has been earned with respect to the Oramed Note, which shall be due and payable on the date on which the outstanding principal amount of the Oramed Note is paid in full. Upon the occurrence and during the continuance of an event of default under the Oramed Note, holders of more than 50% of the aggregate unpaid principal amount of the Oramed Notes may elect to accrue interest at a default rate equal to the lesser of (i) Term SOFR plus 15% or (ii) the maximum rate permitted under applicable law. Voluntary prepayments made before the one-year anniversary of the closing date of the Scilex-Oramed SPA must include a make-whole amount equal to 50% of the additional interest that would accrue on the principal amount so prepaid from the date of such prepayment through and including the maturity date. If the Oramed Note is accelerated upon an event of default, repayment is required at a mandatory default rate of 125% of the principal amount (together with 100% of accrued and unpaid interest thereon and all other amounts due in respect of the Oramed Note). The Oramed Note contains mandatory prepayment provisions requiring use of 70% of net cash proceeds from any Cash Sweep Financing (as defined in the Oramed Note) or advances under the ELOCs (as defined in the Oramed Note) to prepay the outstanding principal after the earlier of April 1, 2024 or full repayment of Acceptable Indebtedness (as defined in the Oramed Note).
|
|
|
|
|
|
|
|
|
|
Debt Repayment Exit Fee |
|
|
|
|
|
|
|
$ 3,100,000
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument, interest rate |
|
|
|
|
|
|
|
4.00%
|
|
|
|
|
|
|
|
|
|
|
|
Debt maturity date |
|
|
|
|
|
|
|
Mar. 21, 2025
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument, owned, percentage |
|
|
|
|
|
|
|
50.00%
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument, default interest rate |
|
|
|
|
|
|
|
15.00%
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument, percentage of interest accrued on principal amount |
|
|
|
|
|
|
|
50.00%
|
|
|
|
|
|
|
|
|
|
|
|
Debt repayment, percentage of mandatory default rate of principal amount |
|
|
|
|
|
|
|
125.00%
|
|
|
|
|
|
|
|
|
|
|
|
Debt repayment, percentage of mandatory default rate of accrued and unpaid interest |
|
|
|
|
|
|
|
100.00%
|
|
|
|
|
|
|
|
|
|
|
|
Percentage of usage of cash proceeds from cash sweep financing |
|
|
|
|
|
|
|
70.00%
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
|
|
|
|
|
|
Mar. 21, 2025
|
|
|
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement | Senior Notes [Member] | Monthly Basis [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt instrument, interest rate |
|
|
|
|
|
|
|
8.50%
|
|
|
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement | Senior Notes [Member] | First installment [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt maturity date |
|
|
|
|
|
|
|
Mar. 21, 2025
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
|
|
|
|
|
|
Mar. 21, 2025
|
|
|
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement | Senior Notes [Member] | Second Installment [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt maturity date |
|
|
|
|
|
|
|
Dec. 21, 2023
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
|
|
|
|
|
|
Dec. 21, 2023
|
|
|
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement | Senior Notes [Member] | Third Installment [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt maturity date |
|
|
|
|
|
|
|
Mar. 21, 2024
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
|
|
|
|
|
|
Mar. 21, 2024
|
|
|
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement | Senior Notes [Member] | Fourth Installment [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt maturity date |
|
|
|
|
|
|
|
Jun. 21, 2024
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
|
|
|
|
|
|
Jun. 21, 2024
|
|
|
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement | Senior Notes [Member] | Five Installment [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt maturity date |
|
|
|
|
|
|
|
Sep. 21, 2024
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
|
|
|
|
|
|
Sep. 21, 2024
|
|
|
|
|
|
|
|
|
|
|
|
Securities Purchase Agreement | Senior Notes [Member] | Six Installment [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt maturity date |
|
|
|
|
|
|
|
Dec. 21, 2024
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
|
|
|
|
|
|
Dec. 21, 2024
|
|
|
|
|
|
|
|
|
|
|
|
Gloperba-Elyxyb Royalty Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage of aggregate net sales |
|
|
4.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No of Calendar Days | Days |
|
|
60
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Royalty Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchased revenue liability |
|
|
$ 500,000
|
|
|
|
|
|
|
|
600,000
|
|
|
|
|
|
|
|
|
Tranche Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ordinary shares issued | shares |
|
|
|
|
|
62,794
|
|
|
|
|
|
|
|
|
|
|
104,848
|
|
|
Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Repayment of debt prinnciple installment |
|
|
|
|
|
|
|
|
|
|
|
|
$ 19,200,000
|
$ 14,100,000
|
|
|
|
|
|
Ordinary shares issued | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,390,443
|
|
|
|
Warrants exercised price | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 40
|
|
|
|
Subsequent Event [Member] | Tranche Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants exercised price | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 36.4
|
|
|
|
ATM Sales Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash proceeds for direct offering |
|
|
|
|
|
|
|
|
|
|
$ 1,760,796
|
|
|
|
|
|
|
|
|
Ordinary shares issued | shares |
|
|
|
|
|
|
|
|
|
|
0
|
2,637
|
|
|
|
|
|
|
|
Oramed Letter Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants execiseable | shares |
|
|
|
|
|
|
|
|
|
|
114,286
|
|
|
|
|
|
|
|
|
Aggregate purchase of private placement warrants (in Shares) | shares |
|
|
|
|
|
|
|
|
|
|
114,286
|
|
|
|
|
|
|
|
|
Oramed Letter Agreement | Senior Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant Purchase | shares |
|
|
|
|
|
|
|
|
|
|
4,000,000
|
|
|
|
|
|
|
|
|
Oramed [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Repurchase of warrants |
$ 14,000,000
|
$ 13,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Scilex Pharma [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total number of shares granted | shares |
|
|
|
142,855
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Scilex Pharma [Member] | Royalty Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Federal funds purchased, average rate paid |
|
|
|
|
|
8.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Scilex Pharma [Member] | Royalty Purchase Agreement [Member] | Senior Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount extinguished and reduced |
|
|
|
|
|
$ 2,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount paid for purchased receivables |
|
|
|
|
|
2,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ZTlido Royalty [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchased revenue liability, current |
|
|
$ 600,000
|
|
|
|
|
|
|
|
$ 500,000
|
|
|
|
|
|
|
|
|
Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares Delivered | shares |
|
|
|
|
|
|
|
|
|
|
92,857
|
|
|
|
|
|
|
|
|
Common Stock [Member] | Tranche Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value of common shares |
|
|
|
|
|
|
|
|
|
|
$ 2,200,000
|
|
|
|
|
|
|
|
|
Common Stock [Member] | Oramed [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value of common shares |
|
|
|
|
|
|
|
|
|
|
1,400,000
|
|
|
|
|
|
|
|
|
Senior Secured Convertible Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument, Periodic Payment |
|
|
|
|
|
12,500,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Senior Secured Convertible Notes [Member] | Securities Purchase Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financing Receivable, Purchased with Credit Deterioration, Amount at Purchase Price, Total |
|
|
|
|
|
5,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase price for the purchased receivables |
|
|
|
|
|
5,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds received from purchase agreement |
|
|
|
|
|
$ 50,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion Price | $ / shares |
|
|
|
|
|
$ 36.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss in changes in fair value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,600,000
|
|
|
|
|
Senior Secured Convertible Notes [Member] | Royalty Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchased revenue liability, current |
|
|
|
|
|
|
|
|
|
|
$ 7,000,000
|
|
|
|
6,800,000
|
|
|
|
|
Payments of debt issuance costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 200,000
|
|
|
|
|
Senior Secured Convertible Notes [Member] | Oramed [Member] | Securities Purchase Agreement | Principal Balance [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reduction of the principal balance |
|
|
|
|
|
$ 22,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Senior Secured Convertible Notes [Member] | Scilex Pharma [Member] | Royalty Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financing Receivable, Purchased with Credit Deterioration, Amount at Purchase Price, Total |
|
|
|
|
|
5,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Paid to royalty investors |
|
|
|
|
|
2,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase price for the purchased receivables |
|
|
|
|
|
$ 5,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Senior Secured Convertible Notes [Member] | October Common Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants exercised price | $ / shares |
|
|
|
|
|
$ 36.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Senior Secured Convertible Notes [Member] | October Common Warrants [Member] | Investor Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ordinary shares issued | shares |
|
|
|
|
|
107,142
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Senior Secured Convertible Notes [Member] | October Common Warrants [Member] | Oramed [Member] | Investor Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ordinary shares issued | shares |
|
|
|
|
|
107,142
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Senior Secured Convertible Notes [Member] | Common Stock [Member] | Investor Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument Repurchased Face Amount |
|
|
|
|
|
$ 22,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Senior Secured Convertible Notes [Member] | Common Stock [Member] | October Common Warrants [Member] | Securities Purchase Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants execiseable | shares |
|
|
|
|
|
214,284
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate purchase of private placement warrants (in Shares) | shares |
|
|
|
|
|
214,284
|
|
|
|
|
|
|
|
|
|
|
|
|
|